The histotripsy-mediated the release of HER2 antigens could be therapeutically relevant in the treatment of HER2+ cancers including breast cancer, gastroesophageal adenocarcinomas, and colon carcinoma. This evidence concerns the gene ERBB2 and breast carcinoma.